

GENNEX LABORATORIES LIMITED  
 REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, MEDAK DIST - 502 325  
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2014

PART I					(Rs. in lakhs)	
Statement of standalone Unaudited Results for the Quarter/Nine Months Ended 31/12/2014					(Rs. in lakhs)	
Sl. No.	Particulars	Quarter Ended		Nine Months Ended		Year ended
		31.12.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations					
	(a) Net Sales/Income from Operations (Net of excise duty)	662.98	1020.06	2262.06	2504.61	3495.31
	(b) Other operating Income	0.60	1.14	2.45	2.72	3.64
	Total Income from operations (net)	663.58	1021.20	2264.51	2507.33	3498.95
2	Expenses					
	(a) Cost of material consumed	415.58	615.95	1437.01	1642.44	2237.96
	(b) Purchases of stock-in-trade	0.00	2.64	50.60	74.98	77.62
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	18.35	18.94	-59.15	-74.19	-3.75
	(d) Employee benefit expense	84.40	83.42	242.74	216.32	307.19
	(e) Depreciation and amortisation expense	25.74	20.53	68.23	61.21	81.99
	(f) Other expenses	116.77	214.06	444.54	505.58	717.38
	Total expenses	660.84	955.54	2183.97	2426.34	3418.39
3	Profit(+)/Loss(-) from operations before other income, finance costs and exceptional items (1-2)	2.74	65.66	80.54	80.99	80.56
4	Other income	12.18	9.74	15.57	18.10	21.15
5	Profit(+)/Loss(-) from ordinary activities before finance costs and exceptional items (3+4)	14.92	75.40	96.11	99.09	101.71
6	Finance costs	10.23	9.91	26.93	23.58	32.03
7	Profit(+)/Loss(-) from ordinary activities before exceptional items (5-6)	4.69	65.49	69.18	75.51	69.68
8	Exceptional items	0	0	0	0	0.12
9	Profit(+)/Loss(-) from ordinary activities before tax (7+8)	4.69	65.49	69.18	75.51	69.80
10	Tax expense	0.00	0	4.50	0	49.18
11	Profit(+)/Loss(-) from ordinary activities after tax (9-10)	4.69	65.49	64.68	75.51	20.62
12	Extraordinary items (net of tax expense Rs. Lakhs)	0	0	0	0	0
13	Net Profit(+)/Loss(-) for the period (11+12)	4.69	65.49	64.68	75.51	20.62
14	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03
15	Reserve excluding Revaluation Reserves					1273.63
16. i	Earning Per Share (before extraordinary items) ( of Rs. 1 each ) (not annualised) :					
	(a) Basic	0.004	0.052	0.051	0.060	0.016
	(b) Diluted	0.004	0.052	0.051	0.060	0.016
16. ii	Earning Per Share (after extraordinary items) ( of Rs. 1 each ) (not annualised) :					
	(a) Basic	0.004	0.052	0.051	0.060	0.016
	(b) Diluted	0.004	0.052	0.051	0.060	0.016

PART II						
Select Information for the Nine Months Ended 31/12/2014						
Sl. No.	Particulars	Quarter Ended		Nine Monts Ended		Year ended
		31.12.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>					
1	Public shareholding					
	- Number of shares	97334670	90966300	97334670	90966300	90966300
	- Percentage of shareholding	76.94	71.91	76.94	71.91	71.91
2	Promoters and Promoters Group Shareholding					
	a) Pledged/Encumbered					
	- Number of shares	25000000	25000000	25000000	25000000	25000000
	- Percentage of shares (as a % of the total share holding of promotor and promotor group)	85.71	70.35	85.71	70.35	70.35
	- Percentage of shares (as a % of the total share capital of the company)	19.76	19.76	19.76	19.76	19.76
	b) Non-encumbered					
	- Number of shares	4168330	10536700	4168330	10536700	10536700
	- Percentage of shares (as a % of the total share holding of promotor and promotor group)	14.29	29.65	14.29	29.65	29.65
	- Percentage of shares (as a % of the total share capital of the company)	3.30	8.33	3.30	8.33	8.33

Particulars	3 months ended	
		31/12/2014
<b>B INVESTOR COMPLAINTS</b>		
Pending at the beginning of the quarter		NIL
Received during the quarter		NIL
Disposed of during the quarter		NIL
Remaining unresolved at the end of the quarter		NIL

- 1) The above results were reviewed by the Audit Committee and were taken on record at the meeting of the Board of Directors held on February 14, 2015.
- 2) Provision for Taxation & AS-22 Deferred Tax will be made at the end of the year.
- 3) Adjustment in respect of compliance with revised Accounting Standard - 15 - 'Employee Benefits' will be carried out at the year end.
- 4) The face value of Equity Shares of Rs. 10/- each has been subdivided into the face value of Rs. 1/- per equity share with effect from 16th December, 2009, the record date. Accordingly the number of shares has increased ten fold. The EPS and aggregate public share holding for the current quarter as well as for other periods has been stated/restated taking into the sub-division of shares.
- 5) The major operations of the company relate to only one segment viz., Bulk Drugs, Biotech Products & Intermediates. As such there is no separate reportable segment under Accounting Standard 17 of Segment Reporting.
- 6) The Company has adopted the useful life of Fixed Assets as indicated in Schedule II of Companies Act, 2013 effective from 1st April, 2014, as a result the depreciation charge for the nine months ended December 31, 2014 is higher by Rs. 1.46 Lacs.
- 7) The Auditors have carried a Limited Review of the above Financial Results.
- 8) Previous period's figures have been regrouped / rearranged wherever considered necessary.

For and on behalf of the Board  
For Gennex Laboratories Limited  
sd/-  
Arihant Baid  
Managing Director

Place: Hyderabad  
Date: 14.02.2015